Index

Page numbers in italics represent figures, those in bold represent tables.

ABCDE approach, 11–13, 25, 48, 68
abscesses, 59, 59
activated protein C, 71–2
acute cholecystitis, 60
acute lung injury (ALI), 17, 24, 72
acute respiratory distress syndrome (ARDS), 16, 19, 64–5, 80–1, 81
acute tubular necrosis (ATN), 17, 24
AIDS, 62–3, 63
anastamotic leak, 11, 57–8, 58
antibiotic resistance, 35
antibiotic therapy, 29, 30, 32–5
choice of empiric antimicrobials, 32–3, 35
endocarditis, 55
immunocompromised patients, 65–6, 65, 66
pneumonia, 51, 51
prudent use, 38
antifungal agents, 66, 66
antiviral agents, 66, 66
arterial waveform analysis, 75–6
aseptic no-touch technique (ANTT), 39
aspiration pneumonia, 52
AVPU scale, 13
AXR (abdominal X-ray), 43
bacteria, in immunocompromised patients, 63
barrier nursing, 63
barriers, to changing behaviour, 84–5, 85, 85, 85
β2-agonists, 80
biomarkers, 4
blood cultures, 30–2, 30
contamination, 33, 33
organisms isolated from, 33, 33
blood pressure monitoring, 73–4, 74
blood tests, 27, 76–7
breathing, 12
cannulation, 26
cardiac output monitoring, 73–6
cardiovascular complications, 15
cardiovascular monitoring, 73–5
cardiovascular support, 71
care bundles, 68–9, 88, 84
cellular response to infection, 21–2
cellulitis, 49, 49
central nervous system complications, 17–18
central venous catheters (CVCs), 27, 40, 71
central venous pressure (CVP) monitoring, 74–5, 74
central venous oxygen saturation (SvO2), 76
change, approaches to, 83–6
cardiogenic shock, 17, 17, 77
communication, 13–14
community-acquired pneumonia (CAP), 32–3, 46, 51
compensation anti-inflammatory response syndrome (CARS), 23
complications, 15–19, 17
computed tomography (CT), 42, 42, 44–5, 45, 65, 65
corticosteroids, 2, 21, 21
cystic fibrosis (CF), 63–4, 63, 66
d–escalation, 34
diabetic foot, 59–60
diagnostic challenges, 2–3
diagnosis criteria, 7–8, 7–8
diuretic administration (DAD), 15–16
disability (as part of ABCDE assessment), 12–13
disseminated intravascular coagulation (DIC), 77, 77
droseragin (activated), 71
Dukes University criteria, 55
early goal-directed therapy (EGDT), 27, 68, 71
echocardiography (ECHO), 75
Exposure (as part of ABCDE assessment), 13
feeding lines, 40
fluid challenges, 27
fungemia, 6
fungus, in immunocompromised patients, 64
future directions, 3–4
gadolinium enhancement, 45
gallbladder, 47, 60
gastronintestinal complications, 18
genetic influences, 79
Glasgow Coma Score, 13
glucose control, 71
GRADE system, 84
gram-negative organisms, 17, 21, 35, 65, 65
gram-positive organisms, 17, 35, 65, 65
H1N1 influenza ('swine flu'), 67
haemoglobin, 27, 69
hand washing, 37
health worker vaccinations, 38
healthcare-associated infection (HCAI), 36–9
heart, in sepsis, 24–4
HMG-CoA reductase, 80
HMGB-1, 3, 81
hospital-acquired pneumonia (HAP), 32–3, 50
human immunodeficiency virus (HIV), 51, 84, 62–5, 82
immune response, 22
hypoxaemia, 15, 16
imaging, 42–7, 42, 45, 46
immunocompromised patients, 62–7, 65
immunodeficiency, causes, 62, 62
immunological complications, 18
improvement project, planning, 85–6
infection, definition, 6
sources, 8, 8, 61, 69
infection control (IC), 29, 36–40, 72
inflammation, definition, 5
inflammatory markers, 45, 56, 59
innate immune system, 20–1, 21
intermittent positive pressure ventilation (IPPV), 24, 69
interventional radiology, 46–7
interventions, 38–9, 83–4
intravenous broad-spectrum antibiotics, 27–8, 33
intravenous immunoglobins (IVIGs), 79–80
investigations, 13, 32
iodinated contrast, 44–5
isolation, 37–8
kidney, in sepsis, 17, 24
knowledge transfer, 3, 83–6, 84
lactate, measurement, 27, 77
Legionella pneumophila, 33
leukocyte reprogramming, 23
limb complications, 18
limitation of support, 72
line-related sepsis, 39–40, 52
lumbar puncture (LP), 13, 45, 54
lung, in sepsis, 24, 15–16
management of surgical patient, 61
Mannheim Peritonitis Index, 57, 57
meningitis, 45, 52–4
MEWS, 7, 7, 11, 11
microbiological sampling, 29–32
methylene blue, 29–50, 50
mitochondria, 22
mixed venous saturation (SvO₂), 76
mortality, 1, 5, 8, 15–16
MRIA, 32, 36–7, 38
multi-organ dysfunction syndrome (MODS), 15
myeloproliferative anaemia, 33
myocardial depression, 2, 15, 23, 23
necrotizing fasciitis, 50, 60
neutropenia, 62–6, 62, 63
nomenclature, 3
novel therapies, 78–82
nuclear medicine, 42, 42, 46
nutritional support, 72
oesophageal Doppler (OD), 73, 75
organ dysfunction, diagnostic criteria, 8
organizational factors, 84–5
osteomyelitis, 45, 56, 59
oxytocin, high-dose, 26
pandemics, 32
pathophysiology, 1–2, 20–4, 23
patient environment action teams (PEATs), 38
Procalcitonin (PCT), 32
pneumoneumonia (PCP), 45–6
perforated viscus, 58
peripheral venous cannulae (PVCs), 39
peritonitis, 57–8
perspective virology, 78
pharmacogenomics, 79
phlebitis, 39, 52–3
phlebitis, 39, 52–3
pulmonary artery flotation catheters (PAFC), 75
pulse oximetry, 12, 26, 76–7
pulse pressure variation (PPV), 76
purpura fulminans, 18, 18
pulmonary artery flotation catheters (PAFC), 75
quality improvement (QI), 83–6
reliability improvement, 83–5
renal complications, 17
renal replacement therapies (RRTs), 17, 72
resuscitation, 25–8, 48, 71
Resuscitation Bundle, 3, 68–9, 84
retention pneumonitis, 44
SIRS, 15–14
screening tools, 8
sepatic-associated encephalopathy (SAE), 17–18
'Sepic Sin', 26, 48
septic arthritis, 59
septic shock, definition, 6
severe acute pancreatitis, 60
severe sepsis, causes, 10
definition, 6
treatment, unsuccessful, 20
severe sepsis screening tools, 8, 10–1
sharps, disposal, 38
signs and symptoms of infection, 6
SIRS, 1, 5–7, 6, 7, 13–16, 76, 60, 77
source isolation, 63
staphylococcal infection, 33
stroke volume variation (SVV), 76
suveillance, 36–7
surviving sepsis campaign (SSC), 3, 68, 74, 78
systemic inflammatory response syndrome (SIRS)
therapeutic targets/agents, 3, 78–9
timet perfection, 22
ToB, T, 23, 23
tools, for improvement, 83
track-and-trigger scoring systems, 11
treatment, unsuccessful, 20
vascular access, 26, 70–1
vascular endothelium, 21–2
ventilation, 69–70, 69, 70
ventilator-induced lung injury (VILI), 69–70
verses, in immunocompromised patients, 64
Visual Infusion Phlebitis (VIP) score, 39
white cell count, 32
wound infections, 58

Index